COMPANY
ReGenTree
Timeline
- Trial start Phase 3: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 source ↗
- Trial start Phase 3: Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 source ↗
- Trial start Phase 3: Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2 source ↗
- Trial start Phase 3: Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1 source ↗
- Trial start Phase 2/Phase 3: Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 source ↗
- Trial start Phase 2: Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye source ↗
- Trial start 2: A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds source ↗
Clinical trials (lead sponsor) 7
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT03937882 | Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 | Phase 3 | Completed | May 24, 2019 | Nov 8, 2020 (actual) |
| NCT05555589 | Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 | Phase 3 | Recruiting | Apr 11, 2023 | Apr 30, 2026 (estimated) |
| NCT02600429 | Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1 | Phase 3 | Terminated | Sep 17, 2015 | Nov 20, 2019 (actual) |
| NCT02974907 | Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2 | Phase 3 | Completed | 2016-11 | 2017-09 (actual) |
| NCT02597803 | Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 | Phase 2/Phase 3 | Completed | 2015-09 | 2016-06 (actual) |
| NCT01387347 | Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye | Phase 2 | Completed | 2011-08 | 2011-10 (actual) |
| NCT00598871 | A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds | 2 | Terminated | 2007-12 | 2009-02 (actual) |